Ke Jin

Years Active: 2020-2023
Publications (10 Years): 7

Sichuan University

Zhejiang University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Sichuan University Nov 21 2018

China

Faculty :: Laboratory of Human Diseases and Immunotherapies, West China Hospital

Zhejiang University Aug 04 2016 - Aug 04 2018

China

Post-doctor :: MOE Laboratory of Biosystems Homeostasis and Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute

Education History

Zhejiang University Sep 01 2009 - Mar 31 2016

China

PHD :: Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences

Publications

Tong Li, Jingjing Ran, Zhiyong Miao, Min Yang, Dachao Mou, Yunhan Jiang, Xiaoqiu Xu, Qibing Xie, Ke Jin
Deficiency of inflammation-sensing protein neuropilin-2 in myeloid-derived macrophages exacerbates colitis via NF-κB activation. The Journal of pathology (2023)
Xiaoqiu Xu, Tong Li, Ke Jin
Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy. Pharmaceutics 14 (5) (2022)
Feng Xie, Xiaoxue Zhou, Peng Su, Heyu Li, Yifei Tu, Jinjin Du, Chen Pan, Xiang Wei, Min Zheng, Ke Jin, Liyan Miao, Chao Wang, Xuli Meng, Hans van Dam, Peter Ten Dijke, Jisheng Liu, Fangfang Zhou
Breast cancer cell-derived extracellular vesicles promote CD8 + T cell exhaustion via TGF-β type II receptor signaling. Nature communications 13 (1) (2022)
Ke Jin, Guofang Shen
Caspase-7 and acid sphingomyelinase: partner repairmans of gasdermin and perforin pores. Signal transduction and targeted therapy 7 (1) (2022)
Ke Jin, Bowen Wu
A new way to maintain CD8 + T-cell quiescence: interaction between CD8α and PILRα. Signal transduction and targeted therapy 7 (1) (2022)
Ke Jin, Fangfang Zhou, Jisheng Liu
Cancer Environment Immunotherapy: targeting TGF-β finds its way towards tissue healing and vasculature remodeling. Signal transduction and targeted therapy 6 (1) (2021)
Ke Jin, Jisheng Liu, Fangfang Zhou
An effective platform for cancer immunotherapy: pooled knockin targeting for genome engineering. Signal transduction and targeted therapy 5 (1) (2020)

Ke Jin.css-eqlu8i{font-size:small;padding-left:4px;}